For Glioblastoma, a New Clinical Trial Fosters Innovation and Hope

March 10, 2022

 • 

Read time:

5-15 mins
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print
Doctors Huddled Masks Book Labcoats
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print
Presented by Health Lab

A new clinical trial at the University of Michigan Rogel Cancer Center offers hope and a new treatment for patients with glioblastoma. This aggressive brain tumor is largely resistant to current treatment, almost always recurs, and comes with a grim prognosis. Daniel Wahl, M.D., Ph.D., lead physician, discusses the trial, their discovery of the causal relationship between high purine levels and glioblastoma radiation resistance, and how to leverage the relationship to make clinical treatments more effective.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.